Menu

Zika’s Effects on Babies Can Show Up Later

The CDC finds one in seven children exposed to the virus in utero experiences health problems by age one.

Aug 7, 2018
Kerry Grens

ABOVE: © ISTOCK, AYWAN88

Around 14 percent of babies whose mothers contracted Zika while pregnant ended up with a birth defect, developmental abnormality, or both, according a report released by the US government today (August 7). Some of the symptoms didn’t show up right away when the babies were born, but emerged in later testing.

“The full range of long-term health problems caused by Zika will remain unknown until these babies mature,” according to a summary of the report from the Centers for Disease Control and Prevention (CDC).

The agency collected health data on 1,450 babies at least one year old who were exposed to Zika in utero and born in a US territory. Six percent of the children had a Zika-associated birth defect, but others’ symptoms showed up later in life. Among 822 babies who did not have a birth defect, 14 had a brain abnormality that was revealed in neuroimaging.

See “Mouse Pups Infected With Zika Show Symptoms Into Adulthood

“That happened because their brain was not growing and developing properly” due to the virus, Margaret Honein, director of the Division of Congenital and Developmental Disorders at the CDC, tells NPR.

In the US and its territories, reports of Zika infections tapered off at the beginning of 2017, with very few cases popping up since then. However, this likely isn’t the end of Zika, and outbreaks may re-emerge.

“I think the bottom line is that the Zika story is not over,” Honein tells The Washington Post. “People may feel like it’s behind us. For these children, it’s not over, and we need to know as much as possible so that we can be prepared” for a future outbreak.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Improved Accuracy in Multiplex Assays

Improved Accuracy in Multiplex Assays

Interference by endogenous antibodies in immunoassays is a well-documented phenomenon. Download this poster to learn about the profound effects that this can have on the data and how development expertise and assay design can eliminate or reduce the effects of endogenous antibodies.

Complete Pathology Solutions: Make Every Minute Count

Complete Pathology Solutions: Make Every Minute Count

From sample collection and handling, to fixation and processing, tissue staining, and covering all your IHC and water purification needs—you can have confidence in the quality of your results with MilliporeSigma's one-stop pathology solution.

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.